A Blueprint for HIV Vaccine Discovery.

[1]  Jamie K. Scott,et al.  Cross-Reactive HIV-1-Neutralizing Human Monoclonal Antibodies Identified from a Patient with 2F5-Like Antibodies , 2013, Journal of Virology.

[2]  J. Luban.  Innate immune sensing of HIV-1 by dendritic cells. , 2012, Cell host & microbe.

[3]  Baoshan Zhang,et al.  Broad and potent neutralization of HIV-1 by a gp41-specific human antibody , 2012, Nature.

[4]  M. Nussenzweig,et al.  Structural basis for germline gene usage of a potent class of antibodies targeting the CD4 binding site of HIV-1 gp120 , 2012, Retrovirology.

[5]  J. van Lunzen,et al.  Expansion of HIV-specific T follicular helper cells in chronic HIV infection. , 2012, The Journal of clinical investigation.

[6]  Michael Y. Gerner,et al.  CD4 T follicular helper cell dynamics during SIV infection. , 2012, The Journal of clinical investigation.

[7]  Lynn Morris,et al.  Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein , 2012, The Journal of experimental medicine.

[8]  Joseph Sodroski,et al.  Subunit organization of the membrane-bound HIV-1 envelope glycoprotein trimer , 2012, Nature Structural &Molecular Biology.

[9]  D. Burton,et al.  Broadly Neutralizing Antibodies Present New Prospects to Counter Highly Antigenically Diverse Viruses , 2012, Science.

[10]  Ron Diskin,et al.  Structural basis for germ-line gene usage of a potent class of antibodies targeting the CD4-binding site of HIV-1 gp120 , 2012, Proceedings of the National Academy of Sciences.

[11]  Thomas B Kepler,et al.  B-cell–lineage immunogen design in vaccine development with HIV-1 as a case study , 2012, Nature Biotechnology.

[12]  Shane Crotty.  The 1‐1‐1 fallacy , 2012, Immunological reviews.

[13]  J. Hong,et al.  Spatial Alterations between CD4+ T Follicular Helper, B, and CD8+ T Cells during Simian Immunodeficiency Virus Infection: T/B Cell Homeostasis, Activation, and Potential Mechanism for Viral Escape , 2012, The Journal of Immunology.

[14]  J. Mascola,et al.  The changing face of HIV vaccine research , 2012, Journal of the International AIDS Society.

[15]  E. Rosenberg,et al.  HIV-Specific Cytolytic CD4 T Cell Responses During Acute HIV Infection Predict Disease Outcome , 2012, Science Translational Medicine.

[16]  Tongqing Zhou,et al.  PGV04, an HIV-1 gp120 CD4 Binding Site Antibody, Is Broad and Potent in Neutralization but Does Not Induce Conformational Changes Characteristic of CD4 , 2012, Journal of Virology.

[17]  John P. Moore,et al.  Occluding the mannose moieties on human immunodeficiency virus type 1 gp120 with griffithsin improves the antibody responses to both proteins in mice. , 2012, AIDS research and human retroviruses.

[18]  Jerome H. Kim,et al.  Vaccine Protection Against Acquisition of Neutralization-Resistant SIV Challenges in Rhesus Monkeys , 2011, Nature.

[19]  Q. Sattentau,et al.  Antigenicity and Immunogenicity in HIV-1 Antibody-Based Vaccine Design. , 2012, Journal of AIDS & clinical research.

[20]  L. Morris,et al.  The Antibody Response against HIV-1. , 2012, Cold Spring Harbor perspectives in medicine.

[21]  H. Schuitemaker,et al.  Longitudinal Analysis of Early HIV-1-Specific Neutralizing Activity in an Elite Neutralizer and in Five Patients Who Developed Cross-Reactive Neutralizing Activity , 2011, Journal of Virology.

[22]  Susan Moir,et al.  Prospects for an HIV vaccine: leading B cells down the right path , 2011, Nature Structural &Molecular Biology.

[23]  Ron Diskin,et al.  Increasing the Potency and Breadth of an HIV Antibody by Using Structure-Based Rational Design , 2011, Science.

[24]  D. Burton,et al.  Rapid development of glycan-specific, broad, and potent anti–HIV-1 gp120 neutralizing antibodies in an R5 SIV/HIV chimeric virus infected macaque , 2011, Proceedings of the National Academy of Sciences.

[25]  Yan Liu,et al.  A Potent and Broad Neutralizing Antibody Recognizes and Penetrates the HIV Glycan Shield , 2011, Science.

[26]  D. Baker,et al.  Computation-Guided Backbone Grafting of a Discontinuous Motif onto a Protein Scaffold , 2011, Science.

[27]  T. Kepler,et al.  Isolation of a Human Anti-HIV gp41 Membrane Proximal Region Neutralizing Antibody by Antigen-Specific Single B Cell Sorting , 2011, PloS one.

[28]  Pham Phung,et al.  Broad neutralization coverage of HIV by multiple highly potent antibodies , 2011, Nature.

[29]  Mario Roederer,et al.  Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing , 2011, Science.

[30]  Ron Diskin,et al.  Sequence and Structural Convergence of Broad and Potent HIV Antibodies That Mimic CD4 Binding , 2011, Science.

[31]  A. Murphy,et al.  Efficient differentiation and function of human macrophages in humanized CSF-1 mice. , 2011, Blood.

[32]  J. Mascola,et al.  Rational design of vaccines to elicit broadly neutralizing antibodies to HIV-1. , 2011, Cold Spring Harbor perspectives in medicine.

[33]  Jamie K. Scott,et al.  Cross-Reactive HIV-1-Neutralizing Human Monoclonal Antibodies Identified from a Patient with 2F5-Like Antibodies , 2011, Journal of Virology.

[34]  D. Burton,et al.  The Glycan Shield of HIV Is Predominantly Oligomannose Independently of Production System or Viral Clade , 2011, PloS one.

[35]  C. Hunter,et al.  Cutting Edge: Dendritic Cell-Restricted Antigen Presentation Initiates the Follicular Helper T Cell Program but Cannot Complete Ultimate Effector Differentiation , 2011, The Journal of Immunology.

[36]  S. Crotty,et al.  ICOS receptor instructs T follicular helper cell versus effector cell differentiation via induction of the transcriptional repressor Bcl6. , 2011, Immunity.

[37]  W. Schief,et al.  Design and characterization of epitope-scaffold immunogens that present the motavizumab epitope from respiratory syncytial virus. , 2011, Journal of molecular biology.

[38]  Todd M. Allen,et al.  Coordinate linkage of HIV evolution reveals regions of immunological vulnerability , 2011, Proceedings of the National Academy of Sciences.

[39]  E. Go,et al.  Characterization of Glycosylation Profiles of HIV-1 Transmitted/Founder Envelopes by Mass Spectrometry , 2011, Journal of Virology.

[40]  B. Haynes,et al.  Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodies. , 2011, Current opinion in immunology.

[41]  Todd M. Allen,et al.  Inhibition of HIV transmission in human cervicovaginal explants and humanized mice using CD4 aptamer-siRNA chimeras. , 2011, The Journal of clinical investigation.

[42]  Akiko Iwasaki,et al.  CD4+ T cells support cytotoxic T lymphocyte priming by controlling lymph node input , 2011, Proceedings of the National Academy of Sciences.

[43]  J. Binley,et al.  Enzyme Digests Eliminate Nonfunctional Env from HIV-1 Particle Surfaces, Leaving Native Env Trimers Intact and Viral Infectivity Unaffected , 2011, Journal of Virology.

[44]  J. Mascola,et al.  147 Rational Design of Envelope Surface Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1 , 2011 .

[45]  Jamie K. Scott,et al.  Comparison of Antibody Repertoires Produced by HIV-1 Infection, Other Chronic and Acute Infections, and Systemic Autoimmune Disease , 2011, PloS one.

[46]  S. Degn,et al.  Trafficking of B cell antigen in lymph nodes. , 2011, Annual review of immunology.

[47]  S. Crotty,et al.  Follicular helper CD4 T cells (TFH). , 2011, Annual review of immunology.

[48]  Matthew S. Lewis,et al.  Profound early control of highly pathogenic SIV by an effector-memory T cell vaccine , 2011, Nature.

[49]  M. Slifka,et al.  Contributions of humoral and cellular immunity to vaccine-induced protection in humans. , 2011, Virology.

[50]  L. Morris,et al.  The Neutralization Breadth of HIV-1 Develops Incrementally over Four Years and Is Associated with CD4+ T Cell Decline and High Viral Load during Acute Infection , 2011, Journal of Virology.

[51]  L. Morris,et al.  Potent and Broad Neutralization of HIV-1 Subtype C by Plasma Antibodies Targeting a Quaternary Epitope Including Residues in the V2 Loop , 2011, Journal of Virology.

[52]  A. Haase,et al.  Early events in sexual transmission of HIV and SIV and opportunities for interventions. , 2011, Annual review of medicine.

[53]  L. Stamatatos,et al.  Computational protein design using flexible backbone remodeling and resurfacing: case studies in structure-based antigen design. , 2011, Journal of molecular biology.

[54]  M. Altfeld,et al.  Characteristics of the Earliest Cross-Neutralizing Antibody Response to HIV-1 , 2011, PLoS pathogens.

[55]  B. Chohan,et al.  HIV-1 superinfection and its implications for vaccine design. , 2010, Current HIV research.

[56]  Michael Meyer-Hermann,et al.  Germinal Center Dynamics Revealed by Multiphoton Microscopy with a Photoactivatable Fluorescent Reporter , 2010, Cell.

[57]  J. Cyster.  B cell follicles and antigen encounters of the third kind , 2010, Nature Immunology.

[58]  M Juliana McElrath,et al.  Induction of immunity to human immunodeficiency virus type-1 by vaccination. , 2010, Immunity.

[59]  Dalya R. Soond,et al.  Phosphoinositide 3-Kinase Activity in T Cells Regulates the Magnitude of the Germinal Center Reaction , 2010, The Journal of Immunology.

[60]  D. Baker,et al.  Elicitation of structure-specific antibodies by epitope scaffolds , 2010, Proceedings of the National Academy of Sciences.

[61]  D. Lowy,et al.  In vivo mechanisms of vaccine-induced protection against HPV infection. , 2010, Cell host & microbe.

[62]  L. Stamatatos,et al.  Computational design of epitope-scaffolds allows induction of antibodies specific for a poorly immunogenic HIV vaccine epitope. , 2010, Structure.

[63]  Tongqing Zhou,et al.  Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01 , 2010, Science.

[64]  Mario Roederer,et al.  Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1 , 2010, Science.

[65]  Dennis R. Burton,et al.  A Limited Number of Antibody Specificities Mediate Broad and Potent Serum Neutralization in Selected HIV-1 Infected Individuals , 2010, PLoS pathogens.

[66]  Dennis R Burton,et al.  Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens , 2010, Proceedings of the National Academy of Sciences.

[67]  John P. Moore,et al.  Lack of complex N-glycans on HIV-1 envelope glycoproteins preserves protein conformation and entry function. , 2010, Virology.

[68]  D. Burton,et al.  Rational antibody-based HIV-1 vaccine design: current approaches and future directions. , 2010, Current opinion in immunology.

[69]  S. Plotkin.  Correlates of Protection Induced by Vaccination , 2010, Clinical and Vaccine Immunology.

[70]  J. Novak,et al.  Glycosylation Patterns of HIV-1 gp120 Depend on the Type of Expressing Cells and Affect Antibody Recognition , 2010, The Journal of Biological Chemistry.

[71]  Felix Campelo,et al.  Crystal Structure of HIV-1 gp41 Including Both Fusion Peptide and Membrane Proximal External Regions , 2010, PLoS pathogens.

[72]  David C Montefiori,et al.  The role of antibodies in HIV vaccines. , 2010, Annual review of immunology.

[73]  Ashley T. Haase,et al.  Targeting early infection to prevent HIV-1 mucosal transmission , 2010, Nature.

[74]  Q. Sattentau,et al.  Analysis of Memory B Cell Responses and Isolation of Novel Monoclonal Antibodies with Neutralizing Breadth from HIV-1-Infected Individuals , 2010, PloS one.

[75]  B. Korber,et al.  HIV-1 vaccine development after STEP. , 2010, Annual review of medicine.

[76]  H. Schuitemaker,et al.  Prevalence of cross-reactive HIV-1-neutralizing activity in HIV-1-infected patients with rapid or slow disease progression , 2009, AIDS.

[77]  Tongqing Zhou,et al.  Structural Basis of Immune Evasion at the Site of CD4 Attachment on HIV-1 gp120 , 2009, Science.

[78]  Richard T. Wyatt,et al.  Breadth of Human Immunodeficiency Virus-Specific Neutralizing Activity in Sera: Clustering Analysis and Association with Clinical Variables , 2009, Journal of Virology.

[79]  Pham Phung,et al.  Broad and Potent Neutralizing Antibodies from an African Donor Reveal a New HIV-1 Vaccine Target , 2009, Science.

[80]  C. Mackay,et al.  The transcriptional repressor Bcl-6 directs T follicular helper cell lineage commitment. , 2009, Immunity.

[81]  D. Dimitrov,et al.  Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: Implications for evasion of immune responses and design of vaccine immunogens , 2009, Biochemical and Biophysical Research Communications.

[82]  Yih-En Andrew Ban,et al.  Challenges for structure-based HIV vaccine design , 2009, Current opinion in HIV and AIDS.

[83]  R. Wyatt,et al.  Immunogenicity of HIV-1 envelope glycoprotein oligomers , 2009, Current opinion in HIV and AIDS.

[84]  Burton E. Barnett,et al.  Bcl6 and Blimp-1 Are Reciprocal and Antagonistic Regulators of T Follicular Helper Cell Differentiation , 2009, Science.

[85]  R. Nurieva,et al.  Bcl6 Mediates the Development of T Follicular Helper Cells , 2009, Science.

[86]  J. Binley,et al.  Structural and immunogenicity studies of a cleaved, stabilized envelope trimer derived from subtype A HIV-1. , 2009, Vaccine.

[87]  Lynn Morris,et al.  Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? , 2009, Nature Medicine.

[88]  E. Go,et al.  Glycosylation site-specific analysis of clade C HIV-1 envelope proteins. , 2009, Journal of proteome research.

[89]  M. Manns,et al.  Humanized mice for modeling human infectious disease: challenges, progress, and outlook. , 2009, Cell host & microbe.

[90]  Lynn Morris,et al.  Antibody Specificities Associated with Neutralization Breadth in Plasma from Human Immunodeficiency Virus Type 1 Subtype C-Infected Blood Donors , 2009, Journal of Virology.

[91]  John P. Moore,et al.  Enzymatic removal of mannose moieties can increase the immune response to HIV-1 gp120 in vivo. , 2009, Virology.

[92]  L. Stamatatos,et al.  Introduction of Exogenous Epitopes in the Variable Regions of the Human Immunodeficiency Virus Type 1 Envelope Glycoprotein: Effect on Viral Infectivity and the Neutralization Phenotype , 2009, Journal of Virology.

[93]  I. Wilson,et al.  HIV-1 and influenza antibodies: seeing antigens in new ways , 2009, Nature Immunology.

[94]  Terri Wrin,et al.  Human Immunodeficiency Virus Type 1 Elite Neutralizers: Individuals with Broad and Potent Neutralizing Activity Identified by Using a High-Throughput Neutralization Assay together with an Analytical Selection Algorithm , 2009, Journal of Virology.

[95]  Andrew D. Luster,et al.  Induction of Robust Cellular and Humoral Virus-Specific Adaptive Immune Responses in Human Immunodeficiency Virus-Infected Humanized BLT Mice , 2009, Journal of Virology.

[96]  Richard T. Wyatt,et al.  Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals , 2009, Nature.

[97]  U. V. von Andrian,et al.  Conduits mediate transport of low-molecular-weight antigen to lymph node follicles. , 2009, Immunity.

[98]  D. Montefiori,et al.  Immune Control of an SIV Challenge by a T Cell-Based Vaccine in Rhesus Monkeys , 2008, Nature.

[99]  Eva K. Lee,et al.  Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans , 2009, Nature Immunology.

[100]  D. Burton,et al.  The Human Immunodeficiency Virus Type 1 Envelope Spike of Primary Viruses Can Suppress Antibody Access to Variable Regions , 2008, Journal of Virology.

[101]  John R. Mascola,et al.  Analysis of Neutralization Specificities in Polyclonal Sera Derived from Human Immunodeficiency Virus Type 1-Infected Individuals , 2008, Journal of Virology.

[102]  Xuesong Yu,et al.  Factors Associated with the Development of Cross-Reactive Neutralizing Antibodies during Human Immunodeficiency Virus Type 1 Infection , 2008, Journal of Virology.

[103]  B. Chohan,et al.  Human Immunodeficiency Virus Type 1 Superinfection Occurs despite Relatively Robust Neutralizing Antibody Responses , 2008, Journal of Virology.

[104]  Lynn Morris,et al.  Profiling the Specificity of Neutralizing Antibodies in a Large Panel of Plasmas from Patients Chronically Infected with Human Immunodeficiency Virus Type 1 Subtypes B and C , 2008, Journal of Virology.

[105]  Magdalini Moutaftsi,et al.  Selective CD4+ T cell help for antibody responses to a large viral pathogen: deterministic linkage of specificities. , 2008, Immunity.

[106]  G. Sapiro,et al.  Molecular architecture of native HIV-1 gp120 trimers , 2008, Nature.

[107]  Dennis R. Burton,et al.  Toward an AIDS Vaccine , 2008, Science.

[108]  E. Go,et al.  Glycosylation site-specific analysis of HIV envelope proteins (JR-FL and CON-S) reveals major differences in glycosylation site occupancy, glycoform profiles, and antigenic epitopes' accessibility. , 2008, Journal of proteome research.

[109]  D. Watkins.  The hope for an HIV vaccine based on induction of CD8+ T lymphocytes--a review. , 2008, Memorias do Instituto Oswaldo Cruz.

[110]  J. Sodroski,et al.  The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus , 2008, Nature Reviews Microbiology.

[111]  Michel C Nussenzweig,et al.  Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. , 2008, Journal of immunological methods.

[112]  J. Binley,et al.  A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120. , 2007, Virology.

[113]  Mark Connors,et al.  Broad HIV-1 neutralization mediated by CD4-binding site antibodies , 2007, Nature Medicine.

[114]  Anthony S Fauci,et al.  An HIV vaccine--evolving concepts. , 2007, The New England journal of medicine.

[115]  Tongqing Zhou,et al.  Structural definition of a conserved neutralization epitope on HIV-1 gp120 , 2007, Nature.

[116]  R. Wyatt,et al.  Rational modifications of HIV-1 envelope glycoproteins for immunogen design. , 2007, Current pharmaceutical design.

[117]  Punnee Pitisuttithum,et al.  Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. , 2006, The Journal of infectious diseases.

[118]  D. Richman,et al.  Lack of neutralizing antibody response to HIV-1 predisposes to superinfection. , 2006, Virology.

[119]  J. Sodroski,et al.  Antibody Binding Is a Dominant Determinant of the Efficiency of Human Immunodeficiency Virus Type 1 Neutralization , 2006, Journal of Virology.

[120]  R. Steinman,et al.  Immunogenicity and efficacy of immunodeficiency virus-like particles pseudotyped with the G protein of vesicular stomatitis virus. , 2006, Virology.

[121]  Karina Yusim,et al.  Role of Maternal Autologous Neutralizing Antibody in Selective Perinatal Transmission of Human Immunodeficiency Virus Type 1 Escape Variants , 2006, Journal of Virology.

[122]  D. Burton,et al.  GP120: target for neutralizing HIV-1 antibodies. , 2006, Annual review of immunology.

[123]  J. Binley,et al.  Nature of Nonfunctional Envelope Proteins on the Surface of Human Immunodeficiency Virus Type 1 , 2006, Journal of Virology.

[124]  J. Mascola,et al.  Characterization of Antibody Responses Elicited by Human Immunodeficiency Virus Type 1 Primary Isolate Trimeric and Monomeric Envelope Glycoproteins in Selected Adjuvants , 2006, Journal of Virology.

[125]  M Anthony Moody,et al.  Antibody polyspecificity and neutralization of HIV-1: a hypothesis. , 2006, Human antibodies.

[126]  D. Montefiori,et al.  Induction of Neutralizing Antibodies against Human Immunodeficiency Virus Type 1 Primary Isolates by Gag-Env Pseudovirion Immunization , 2005, Journal of Virology.

[127]  Robyn L Stanfield,et al.  Antibody vs. HIV in a clash of evolutionary titans. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[128]  Xiping Wei,et al.  Human Immunodeficiency Virus Type 1 env Clones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies , 2005, Journal of Virology.

[129]  Renate Kunert,et al.  Cardiolipin Polyspecific Autoreactivity in Two Broadly Neutralizing HIV-1 Antibodies , 2005, Science.

[130]  Kenneth H Mayer,et al.  Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. , 2005, The Journal of infectious diseases.

[131]  Christoph Grundner,et al.  Analysis of the neutralizing antibody response elicited in rabbits by repeated inoculation with trimeric HIV-1 envelope glycoproteins. , 2005, Virology.

[132]  Ping Zhu,et al.  Antibody Domain Exchange Is an Immunological Solution to Carbohydrate Cluster Recognition , 2003, Science.

[133]  D. Burton,et al.  Heterogeneity of Envelope Molecules Expressed on Primary Human Immunodeficiency Virus Type 1 Particles as Probed by the Binding of Neutralizing and Nonneutralizing Antibodies , 2003, Journal of Virology.

[134]  D. Burton.  Antibodies, viruses and vaccines , 2002, Nature Reviews Immunology.

[135]  O. Schwartz,et al.  Enhanced Presentation of Major Histocompatibility Complex Class I-Restricted Human Immunodeficiency Virus Type 1 (HIV-1) Gag-Specific Epitopes after DNA Immunization with Vectors Coding for Vesicular Stomatitis Virus Glycoprotein- Pseudotyped HIV-1 Gag Particles , 2002, Journal of Virology.

[136]  D. Katzenstein,et al.  Maternal HIV‐1 Antibody and Vertical Transmission in Subtype C Virus Infection , 2002, Journal of acquired immune deficiency syndromes.

[137]  D. Burton,et al.  The antiviral activity of antibodies in vitro and in vivo , 2001, Advances in Immunology.

[138]  Paul W. H. I. Parren,et al.  Broadly Neutralizing Antibodies Targeted to the Membrane-Proximal External Region of Human Immunodeficiency Virus Type 1 Glycoprotein gp41 , 2001, Journal of Virology.

[139]  K. Tomer,et al.  Mass spectrometric characterization of the glycosylation pattern of HIV-gp120 expressed in CHO cells. , 2000, Biochemistry.

[140]  S. Spector,et al.  Lack of autologous neutralizing antibody to human immunodeficiency virus type 1 (HIV-1) and macrophage tropism are associated with mother-to-infant transmission. , 1999, The Journal of infectious diseases.

[141]  E. Hunter,et al.  A Conserved Tryptophan-Rich Motif in the Membrane-Proximal Region of the Human Immunodeficiency Virus Type 1 gp41 Ectodomain Is Important for Env-Mediated Fusion and Virus Infectivity , 1999, Journal of Virology.

[142]  J. Sodroski,et al.  The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. , 1998, Science.

[143]  G. Wang,et al.  Induction of the , 1996 .

[144]  Q. Sattentau,et al.  Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer , 1995, The Journal of experimental medicine.

[145]  B. Murphy,et al.  Cytotoxic T cells specific for a single peptide on the M2 protein of respiratory syncytial virus are the sole mediators of resistance induced by immunization with M2 encoded by a recombinant vaccinia virus , 1995, Journal of virology.

[146]  D R Burton,et al.  Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1 , 1994, Journal of virology.

[147]  G Himmler,et al.  A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1 , 1993, Journal of virology.

[148]  E. Halapi,et al.  Neutralizing antibodies and viral characteristics in mother‐to‐child transmission of HIV‐1 , 1993, AIDS.

[149]  J. Albert,et al.  Mother-to-child transmission of human immunodeficiency virus type 1: correlation with neutralizing antibodies against primary isolates. , 1993, The Journal of infectious diseases.

[150]  G R Pilkington,et al.  Molecular profile of an antibody response to HIV-1 as probed by combinatorial libraries. , 1993, Journal of molecular biology.

[151]  J. Ulmer,et al.  Heterologous protection against influenza by injection of DNA encoding a viral protein. , 1993, Science.

[152]  R. Hancock,et al.  Protection in simian immunodeficiency virus-vaccinated monkeys correlates with anti-HLA class I antibody response , 1992, The Journal of experimental medicine.

[153]  Robert T. Chen,et al.  Measles antibody: reevaluation of protective titers. , 1990, The Journal of infectious diseases.

[154]  M. Oldstone,et al.  Cytotoxic T lymphocyte control of acute lymphocytic choriomeningitis virus infection: interferon gamma, but not tumour necrosis factor alpha, displays antiviral activity in vivo. , 1989, The Journal of general virology.

[155]  T. Mizuochi,et al.  Carbohydrate structures of the human-immunodeficiency-virus (HIV) recombinant envelope glycoprotein gp120 produced in Chinese-hamster ovary cells. , 1988, The Biochemical journal.